Rentschler Biopharma launched an expanded service offering at its dedicated Advanced Therapy Medicinal Products (ATMP) site in Stevenage, U.K. The company introduced a new lentiviral vector manufacturing (LVV) toolbox to complement its existing adeno-associated viral (AAV) vector services.
With increased research, as well as positive clinical results across a wide range of therapeutic applications, LVVs are becoming increasingly prominent in the advanced therapy space, according to Christiane Bardroff, COO at Rentschler Biopharma, adding that gene transfer using LVVs has been applied to treat several genetic diseases, such as beta-thalassemia. Lentiviral vectors have also been used to modify T-cells by introducing genes to generate immunity against cancer, she continued.
“We made a strategic investment in the cell and gene therapy sector, starting with adeno-associated viral vector services, so we could offer our development and manufacturing expertise and sector experience to support innovators in this fast-developing space,” said Bardroff. “Rentschler Biopharma is now well positioned to serve the demand of therapeutic developers who utilize LVVs for gene modulation, including cell therapies, with the addition of lentiviral vector manufacturing to its portfolio.”
The company reports that its advanced therapies facility offers customized solutions designed to help clients accelerate their viral vector programs at every stage, featuring novel toolboxes for AAVs and LVVs that are license-free. Clients also benefit from Rentschler Biopharma’s royalty-free, proprietary HEK293 cell line, which offers additional time and cost savings for advanced therapy projects, noted Robert Panting, general manager, Rentschler ATMP.
“By integrating lentiviral vector process development and manufacturing to our services, we are better serving the market by meeting the growing needs of the evolving and vibrant global advanced therapies sector,” said Panting.
